Kernel has initiated a study on cognitive decline utilising the Flow2 neuroimaging technology.
The Neurology Center of Southern California, a Profound Research site and one of Kernel’s collaborators in the trial, carried out measurements on the first group of patients.
The study leverages the advanced capabilities of Flow2 neuroimaging technology to identify mild cognitive impairment (MCI) and assess the severity of MCI symptoms.
It will be achieved by analysing neurophysiological data from Flow2 obtained during a series of cognitive tasks and resting state measurements.
The study cohorts include individuals diagnosed with MCI and healthy controls, all aged over 55. These groups are currently accepting participants from Southern California.
Kernel aims to develop advanced biomarkers based on brain activity by utilising the portable and user-friendly Flow2 technology.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
These biomarkers are expected to revolutionise the method of screening for cognitive function-related diseases.
Kernel CEO Ryan Field said: “For the first time, there is a tool available that provides a robust measure of cognition and brain health. Through this observational study, we are demonstrating that Kernel Flow can be easily used in primary care settings to monitor brain function.
“By identifying biomarkers of the condition at its source —the brain—we aspire to enable earlier detection and better interventions for all forms of dementia. In the future, we plan to combine our measurement with other biomarkers to provide a comprehensive picture of brain function.
“Just like cardiac disease is monitored, screened and diagnosed with a battery of low-cost tests, we expect that identifying diseases of the brain will become similarly data-driven.”